

Title page

1

2

3 **Prevalence and factors associated with sarcopenia among older adults in a**
4 **post-acute hospital in Singapore**

5

6 Tan You Mei Charmaine MMED (Fam Med)^{1,2}, Sharna Seah Si Ying Ph.D. (Public
7 Health)³, Lim Yanshan Doris Msc AdvPT⁴, Koh Siew Van BAppSc (OT)⁴, Ganeshan
8 Karthikeyan BPT⁴, Xia Jiawen Olivia MSA (Data and Analytics)³, Low Xuan Lin DPHM⁵,
9 Quek Hui Yi GCE-A⁶, Ong Shuyi Andrea MD¹, A/Prof Low Lian Leng (Fam Med)
10 FCFP(S)^{1,2}, Aw Junjie MMED (Fam Med) FCFP(S)^{1,2}

11

12 ¹ Post-Acute and Continuing Care Department, Outram Community Hospital,
13 SingHealth Community Hospitals, Singapore

14 ² SingHealth Duke-NUS Family Medicine Academic Clinical Program, Singapore

15 ³ Research and Translational Innovation Office, SingHealth Community Hospitals,
16 Singapore

17 ⁴ Rehabilitation Department, Outram Community Hospital, SingHealth Community
18 Hospitals, Singapore

19 ⁵ Department of Health and Social Science, Singapore Institute of Technology,
20 Singapore

21 ⁶ Department of Biological Sciences, National University of Singapore, Singapore

22

23 Corresponding author: Dr. Aw Junjie. aw.junjie@singhealth.com.sg

24 Word count abstract: 213

25 Word count "Main text": 3290

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26

27 Funding source:

28 This study was funded by the 2021 SingHealth Regional Health System (RHS):
29 Population-based, Unified, Learning System for Enhanced and Sustainable Health
30 (PULSES) Grant ID: CGOCT21S06.

31

32 Impact statement: Our study found that 1 in 2 older adults are sarcopenic and 1 in 3
33 older adults are severely sarcopenia in the post-acute settings with associations to
34 increased age, male sex, low physical activity, cognitive impairment and inverse
35 associations with higher BMI and hip circumference.

36

37 **Key points:**

38 1) One in two older adults are sarcopenic and one in three older adults are severely
39 sarcopenic in a post-acute setting, indicating a high prevalence of sarcopenia and
40 underscoring the urgency to address sarcopenia now.

41 2) Age, sex, physical activity, hip circumference and BMI are associations with
42 sarcopenia. In addition, cognition is also associated with severe sarcopenia.

43 3) This is the first inpatient study in Singapore looking at sarcopenia associations and
44 it lends support to global literature on associations of sarcopenia and allows for
45 possible interventions to target modifiable risk factors in sarcopenia.

46

47 Word count "key points": 93

48

49 **Abstract**

50 **Background:**

51 Sarcopenia is common in older adults worldwide, but its prevalence varies widely
52 owing to differences in diagnostic criteria, population sampled, and care setting. We
53 aimed to determine the prevalence and factors associated with sarcopenia in
54 patients aged 65 and above admitted to a post-acute hospital in Singapore.

55

56 **Methods:**

57 This was a cross-sectional study of 400 patients recruited from a community hospital
58 in Singapore. Data including socio-demographics, physical activity, nutritional status,
59 cognition, clinical and functional status, as well as anthropometric measurements
60 were collected. Sarcopenia was defined using the Asian Working Group for
61 Sarcopenia 2019 criteria (AWGS2019).

62

63 **Results:**

64 Of the 383 patients with complete datasets, overall prevalence of sarcopenia was
65 54% while prevalence of severe sarcopenia was 38.9%. Participants with increased
66 age, male gender and a low physical activity level were more likely to be sarcopenic,
67 while those with higher hip circumference and higher BMI of ≥ 27.5 m/kg² were less
68 likely to be sarcopenic. Other than the above-mentioned variables, cognitive
69 impairment was also associated with severe sarcopenia.

70

71 **Conclusions:**

72 There is a high prevalence of sarcopenia in older patients admitted to a post-acute
73 hospital in Singapore. There is an urgent need to address this important clinical
74 syndrome burden and to identify patients at higher risk of sarcopenia in post-acute
75 settings in Singapore for early intervention.

76 Word count “abstract”: 213

77 **Main text**

78

79 Introduction

80 The proportion of older adults worldwide is rapidly growing, with projected doubling
81 by 2050.(1) 16.6% of Singapore’s residents were aged 65 and above in 2022, and this
82 is rising 4-5.6% year on year.(2) Increased life expectancy globally is not equitable with
83 healthy life expectancy.(3) Echoing this, the United Nations General Assembly has
84 declared 2021-2030 the Decade of Healthy Ageing.(4) Increased age is associated with
85 frailty and sarcopenia.(5-8) These geriatric syndromes herald increased healthcare
86 utilization and costs from associated morbidity and mortality.(9-12) Among inpatients
87 undergoing rehabilitation, sarcopenia had been reported to be associated with worse
88 recovery of function and lower rate of home discharge in hospitalized adults
89 undergoing rehabilitation.(13)

90

91 Sarcopenia is common in older adults worldwide, but it’s prevalence varies widely
92 owing to differences in diagnostic criteria, population sampled, and care setting.(14)
93 Sarcopenia prevalence reported in overseas studies was 26.9 – 58% in inpatient post-
94 acute and rehabilitation wards and 50.9 - 60.2% in daycare facilities.(11, 15-18)
95 Sarcopenia has been reported to be associated with age, gender, marital status,
96 comorbidities, smoking, physical activity, BMI, waist circumference, hip
97 circumference, nutrition, and cognition.(13, 15-24)

98

99 Several studies in Singapore had reported sarcopenia prevalence among varying
100 population groups in the community.

101

102 For example, sarcopenia prevalence in a community sample of individuals aged 21-90
103 years old compared to those aged 60 years and above was 13.6% and 32.2%
104 respectively.(21) Another study reported sarcopenia prevalence of 76% among
105 community ambulant adults aged 65 and above who were at medium or high risk of
106 malnutrition.(22) The prevalence of sarcopenia in primary care and specialist
107 outpatient clinics ranged from 27.4% in patients aged 60-89 years old with Type 2
108 Diabetes Mellitus using AWGS criteria, to 44% in patients aged 65 and above based
109 on SARC-F questionnaire only.(19, 25)

110

111 However, till date there is none investigating sarcopenia prevalence using established
112 recommended criteria in the inpatient setting. We aim to determine the prevalence
113 of sarcopenia, severe sarcopenia and their associations in an inpatient post-acute
114 hospital setting in Singapore.

115

116 Materials and Methods

117 Setting

118 This cross-sectional study was conducted from May to November 2022 at Outram
119 Community Hospital (OCH).

120 A community hospital in Singapore is a purpose built hospital to provide medical,
121 nursing and rehabilitation care for patients who require a short period of continuation
122 of care after their stay in the acute hospitals i.e. post-acute care before being
123 discharged into the community.(26)

124 Admissions into OCH come from the Singapore General Hospital (SGH), the largest co-
125 located acute tertiary hospital in Singapore servicing the southeastern region of
126 Singapore.

127

128 Study participants and recruitment

129 All patients aged 65 years old and above admitted to OCH under subacute or
130 rehabilitation service from 17 May to 16 November 2022 were consecutively screened
131 based on eligibility criteria. Participants who were unable to understand English or
132 Mandarin, refused to participate, or unable to give informed consent or follow
133 instructions due to conditions such as neuropsychiatric or neurocognitive disease
134 were excluded. Additional excluded participants included those who were terminally
135 ill; medically unstable; had conditions which precluded sarcopenia assessment such
136 as anyone with a cardiac pacemaker, an implantable defibrillator, amputation of
137 limb(s), intravenous hydration, fluid overload and had temporary restrictions in
138 weightbearing status of upper or lower limbs.

139

140 Eligible participants were then recruited after written informed consent was obtained.
141 All participants recruited were assigned to a unique serial number in order to delink
142 and deidentify them. All data was collected during the inpatient stay in OCH, with no
143 further follow-up or contact after discharge.

144

145 This study was approved by SingHealth Centralized Institutional Review board (CIRB
146 Ref 2021/2817).

147

148 Data Collection

149 All interviewers received standardized training on interview techniques with trial
150 interviews held with trainer to ensure fidelity. Face-to-face interviews with the
151 patients were conducted in Mandarin and English.

152

153 Data collected included 1) demographics (age, sex, race, marital status, living setup,
154 type of dwelling and highest educational qualification); 2) physical activity and
155 sedentary time; 3) nutritional status; 4) cognition; and 5) other clinical parameters
156 (weight, height, smoking history, Modified Barthel Index (MBI) scores on admission,
157 Charlson Comorbidity Index (CCI); history of COVID-19 infection; waist circumference
158 (WC); hip circumference (HC) and Rehabilitation Diagnostic Groups (RDGs)
159 classification, an administrative framework to group patients admitted for
160 rehabilitation so as to facilitate transition and collaboration across the stakeholders
161 in the care spectrum.

162

163 Physical activity level and sedentary time were assessed using the Global Physical
164 Activity Questionnaire (GPAQ), which was developed by WHO with standardized
165 approach and question guide available both in English and Mandarin translations, and
166 used in multiple Singapore studies including the National Health Survey 2010 and
167 2019.(21, 27-32) As per the GPAQ, participants' sedentary time in minutes per day
168 and their physical activity level (low and moderate or high) were collected.(33)

169

170 The 3-Minute Nutritional Screening (3-MinNS) tool, developed in Singapore and
171 validated for medical and surgical inpatients in a Singapore hospital, was used to
172 screen nutritional status.(34, 35) Participants were grouped into low (0-2), moderate
173 (3-4), or severe (5-9) malnutrition risk.(34)

174

175 Cognitive assessment was done using the Chinese Mini Mental State Examination
176 (CMMSE), which was also validated locally in English and Mandarin.(36) Those with
177 CMMSE scores of 23 and below were considered as having impaired cognition.(37)

178

179 The participants' inpatient medical records were accessed to retrieve information
180 regarding the following: MBI on admission; CCI; history of COVID-19 infection; RDGs;
181 weight (in kilogrammes) and height (in metres) on admission.

182

183 Body mass index (BMI) was calculated as body weight divided by square of height
184 (kg/m^2). Cut-offs were based on WHO BMI risk categories for cardiovascular disease
185 and diabetes in Asian populations.(38)

186

187 Anthropometry

188 Waist circumference (WC) was measured using a stretch-resistant tape at the
189 midpoint between the lower margin of the least palpable rib and the top of the iliac
190 crest. Waist circumference cut-offs were determined as per The International
191 Diabetes Federation (IDF) consensus worldwide definition for metabolic
192 syndrome.(39)

193

194 Hip circumference (HC) was measured around the widest portion of the buttocks.(40)
195 Waist-hip ratio (WHR) was calculated by dividing WC over HC. Cut-offs for WHR were
196 based on World Health Organization (WHO), redefining obesity - the Asia-Pacific
197 perspective.(41)

198

199 Sarcopenia assessment

200 There have been several proposed diagnostic algorithms for sarcopenia. In 2010, the
201 European Working Group on Sarcopenia in Older People (EWGSOP) proposed the first
202 practical clinical definition and diagnostic criteria for sarcopenia based on assessment

203 of muscle mass, muscle strength and physical performance.(42) This was revised in
204 2018 to EWSOP2, which used low muscle strength as the primary parameter of
205 sarcopenia.(10) To address differences in cut-off values of measurements in Asian
206 populations from Europeans, an Asian consensus was derived by the Asian Working
207 Group for Sarcopenia (AWGS) in 2014 and revised in 2019.(43, 44)

208

209 In our study, sarcopenia was assessed and diagnosed using criteria as per
210 AWGS2019(44). Sarcopenia was diagnosed in the presence of low muscle mass, with
211 either low muscle strength or low physical performance (PP). Those with low muscle
212 mass, low muscle strength, and low PP, were further subclassified as “severe
213 sarcopenia” for sub-group analyses.(44)

214

215 *Muscle mass*

216 Appendicular skeletal muscle mass (ASM) was determined using a multifrequency
217 bioelectrical impedance analysis (BIA) InBody S10 Body Composition Monitor. ASMI
218 was calculated by dividing ASM by height squared (kg/m^2). BIA measurements were
219 conducted under standardised protocols i.e. before therapy sessions, in supine
220 position with limbs abducted and ensuring no contact with metal frame of bed.(45)
221 Low muscle mass was defined as appendicular skeletal muscle mass index (ASMI)
222 $<7\text{kg}/\text{m}^2$ in males and $<5.7\text{kg}/\text{m}^2$ in females.

223

224 *Muscle strength*

225 Muscle strength was assessed via handgrip strength (HGS) which was measured using
226 a dynamometer (BASELINE 12-0240 standard hydraulic hand dynamometer) in seated
227 posture, with shoulder adducted and elbow flexed to 90 degrees and forearm in
228 neutral as recommended by American Society of Hand Therapists.(46) The maximum

229 reading from at least two trials using either hand in a maximum-effort isometric
230 contraction was used for analysis.(44) Low muscle strength was defined as handgrip
231 strength (HGS) <28kg in males and <18kg in females.

232

233 *Physical Performance*

234 Low PP was defined as gait speed <1.0m/s over 6-metre walk (6mGS), or 5-time chair
235 stand test (5CST) requiring ≥ 12 s, or Short Physical Performance Battery (SPPB) score
236 of ≤ 9 .

237

238 6mGS was measured as time taken to walk 6m at a normal pace from a moving start,
239 without deceleration, with average of two trials taken as the recorded speed
240 (m/s)(44). Walking aids were permitted if necessary and documented if it was used.

241 5CST was measured as the time taken to rise and sit five times as quickly as possible
242 with no contact against the back of the chair and maximal extension of knees(47).

243 SPPB is a 3-part performance-based test of balance, gait speed, and 5CST, with a score
244 of 0 to 12.

245

246 *Statistical analyses*

247 Categorical variables were presented as proportions and continuous variables
248 summarized as means \pm SD or medians with interquartile ranges [IQR (25th
249 percentile, 75th percentile)] as appropriate. Pearson chi-square test was used to
250 compare categorical variables and logistic regression to compare continuous variables
251 as appropriate for univariate analyses.

252 Multivariate logistics regression was done on all variables investigated to arrive at
253 adjusted odds ratio with 95% confidence interval (CI) associated with sarcopenia

254 outcomes. Similarly multinomial regression was done on all variables to calculate
255 adjusted odds ratio associated with severe sarcopenia outcomes.
256 All analyses were two-tailed and p value <0.05 was considered statistically significant.
257 Statistical analysis was performed using Stata Version 17 (StataCorp, College Station,
258 TX, USA).

259

260 Results

261 A total of 400 patients were recruited, of which 17 (4%) had incomplete data due to
262 discharge or transfer to acute hospital for acute medical issues. Hence, 383 (96%)
263 patients with complete data were analysed in this study. Figure 1 shows the process
264 of identifying sarcopenia in our study population using AWGS2019 diagnostic
265 algorithm.

266

267 *Prevalence of sarcopenia and severe sarcopenia*

268 Prevalence of sarcopenia using AWGS 2019 criteria in our study population was 54.0%
269 (n=207) with 66.4% of males being sarcopenic and 45.9% of females being sarcopenic.
270 Prevalence of severe sarcopenia in our cohort was 38.9% (n=149).

271

272 *Characteristics of study population and unadjusted odds ratio*

273 Table 1 illustrates the characteristics of our participants with corresponding
274 unadjusted odds ratios of sarcopenia. The median age of participants was 75 years
275 old (IQR: 70-81), with more females (60.3%) than male participants, and majority (93%)
276 were Chinese. Slightly more than half (56.1%) were currently married. Majority (91.9%)
277 live in public governmental housing (Housing Development Board (HDB) apartments).
278 About two thirds (60.4%) of our cohort have less than secondary school education and

279 only 20% of participants were smokers or ex-smokers. 2/3 of our participants had CCI
280 more than “0”. 62% of participants were not known to be infected by COVID-19 prior
281 to recruitment into study.

282

283 Slightly more than half (56.4%) were at moderate or high risk of malnutrition. Physical
284 activity level was evenly distributed with half (50.9%) of the participants assessed to
285 have low physical activity level. Approximately half of our participants (49.9%) had
286 CMMSE 23 or less. Slightly over half (57.4%) of participants had BMI of 23kg/m² or
287 more, while approximately 2/3 had an elevated waist circumference and waist-hip
288 ratio.

289

290 Half (54.1%) of the participants had an MBI score of 0-60 on admission, indicating
291 severe to total dependency in activities of daily living. Participants were mostly
292 admitted for rehabilitation (RDG) due to musculoskeletal conditions (48.8%), followed
293 by deconditioning (18.5%), others (14.4%), hip fracture (11.5%), and stroke (5.1%).

294

295 Table 1: Characteristics of study population and factors associated with sarcopenia on univariate analysis

Characteristic	Total (n= 384)	Non-Sarcopenic (n = 176)	Sarcopenia (n =208)	Unadjusted OR (95% CI)
Age in years, median (IQR)	75 (70, 81)	74 (69, 78)	77 (72, 82)	1.09 (1.06-1.13)
Sex, n (%)				
Male	152 (39.6)	51 (29.0)	101 (48.8)	2.34 (1.53-3.57)
Female	231 (60.3)	125 (71.0)	106 (51.2)	1
Race, n (%)				
Chinese	356 (93)	160 (90.9)	196 (94.7)	1
Malay	16 (4.2)	11 (6.25)	5 (2.4)	0.37 (0.13-1.09)

Indian	8 (2.1)	4 (2.27)	4 (1.9)	0.82 (0.20-3.32)
Others (2 Eurasians, 1 Sikh)	3 (0.8)	1 (0.6)	2 (1.0)	1.63 (0.15-18.17)
Current Marital Status, n (%)				
Single / Widowed / Divorced / Separated	168 (43.9)	67 (38.1)	101 (48.8)	1.55 (1.03-2.33)
Currently married	215 (56.1)	109 (61.9)	106 (51.2)	1
Living Setup, n (%)				
Alone	85 (22.2)	33 (18.8)	52 (25.1)	1.45 (0.89-2.38)
With someone	298 (77.8)	143 (81.3)	155 (74.9)	1
Housing Type, n (%)				
HDB (public housing)	352 (91.9)	163 (92.6)	189 (91.3)	0.89 (0.42-1.88)
Condominium/Landed (private housing)	30 (7.8)	13 (7.4)	17 (8.2)	1
Others (overseas property)	1 (0.3)	0 (0)	1 (0.5)	-
Highest Educational Qualification, n (%)*				
Below GCE "N" or "O" levels	230 (60.4)	100 (56.8)	130 (63.4)	1.32 (0.87-1.99)
GCE "N" or "O" level and above	151 (39.6)	76 (43.2)	75 (36.6)	1
Smoking history, n (%)				
Never smoker	308 (80.4)	148 (84.1)	160 (77.3)	1
Ex or Current smoker	75 (19.6)	28 (15.9)	47 (22.7)	1.55 (0.92-2.61)
Charlson Comorbidity Index, n (%)				
0	130 (33.9)	72 (40.9)	58 (28.0)	1
1 and 2	173 (45.2)	74 (42.1)	99 (47.8)	1.66 (1.05-2.63)
3 and more	80 (20.9)	30 (17.1)	50 (24.2)	2.07 (1.17-3.66)
Ever infected by COVID-19 before recruitment into study, n (%)				
No	237 (61.9)	113 (64.2)	124 (59.9)	1
Yes	146 (38.1)	63 (35.8)	83 (40.1)	1.20 (0.79-1.82)
Malnutrition Risk n (%)*				

No risk	170 (44.6)	112 (64.0)	58 (28.2)	1
Moderate risk	124 (32.6)	40 (22.9)	84 (40.8)	4.06 (2.48-6.63)
Severe risk	87 (22.8)	23 (13.1)	64 (31.1)	5.37 (3.03-9.52)
Physical Activity, n (%)				
Low	195 (50.9)	78 (44.3)	117 (56.5)	1.63 (1.09-2.45)
Moderate to high	188 (49.1)	98 (55.7)	90 (43.5)	1
Sedentary Time in minutes/day, median (interquartile range 25 th centile, 75 th centile)				
	800 (690-895)	800 (685-890)	810 (710-900)	1.00 (0.9997-1.0022)
Cognition, n (%)				
CMMSE Score 23 and less	191 (49.9)	73 (41.5)	118 (57.0)	1.87 (1.25-2.81)
CMMSE Score 24 and more	192 (50.1)	103 (58.5)	89 (43.0)	1
BMI ^a , kg/m ² (%)				
Less than 18.5	56 (14.6)	3 (1.7)	53 (25.6)	4.31 (1.23-15.17)
18.5-22.9	107 (27.9)	21 (11.9)	86 (41.6)	1
23-27.4	133 (34.7)	74 (42.1)	59 (28.5)	0.19 (0.11-0.35)
27.5 and above	87 (22.7)	78 (44.3)	9 (4.4)	0.03 (0.01-0.07)
Waist Circumference ^b , cm (%)				
Males ≤90; Females ≤80	128 (33.4)	20 (11.4)	108 (51.2)	8.51 (4.96-14.59)
Males >90; Females >80	255 (66.6)	156 (88.6)	99 (47.8)	1
Hip Circumference in cm, mean (SD)				
	94.2 (8.9)	99.6 (7.9)	89.6 (6.9)	0.83 (0.79-0.86)
Waist-Hip Ratio (WHR) ^c , n (%)				
Males 1.0 and below Females 0.85 and below	119 (31.1)	35 (19.9)	84 (40.6)	2.75 (1.73-4.37)
Males more than 1.0 Females more than 0.85	264 (68.9)	141 (80.1)	123 (59.4)	1
MBI score on admission, n (%)				

MBI 0-60 (severe to total dependency)	207 (54.1)	80 (45.5)	127 (61.4)	1.91 (1.27-2.86)
MBI 61-100 (moderate dependency to functional independence)	176 (46.0)	96 (54.6)	80 (38.7)	1
Admission RDG, n (%)				
Deconditioning	71 (18.5)	16 (9.1)	55 (26.6)	5.25 (2.80-9.85)
Others (e.g. IV antibiotics, wound care, malignancy)	55 (14.4)	16 (9.1)	39 (18.8)	3.72 (1.94-7.14)
Stroke	26 (6.8)	9 (5.1)	17 (8.2)	2.88 (1.22-6.81)
Hip fracture	44 (11.5)	22 (12.5)	22 (10.6)	1.53 (0.79-2.95)
Musculoskeletal conditions	187 (48.8)	113 (64.2)	74 (35.8)	1

296
297
298
299
300

^a Cut-offs as per WHO BMI risk categories for cardiovascular disease and diabetes in Asian populations
^b Cut-offs as per IDF
^c Cut-offs as per WHO
[#] p-value required for significance after Bonferroni correction is 0.0083
*missing data n=2

301

302 *Factors associated with sarcopenia*

303 Older age [OR 1.06 (1.01-1.12)], male sex [OR 2.80 (1.12-7.02)] and low physical
304 activity [OR 2.13 (1.17-3.89)] were associated with sarcopenia. Higher BMI more than
305 or equal to 27.5 [OR 0.16 (0.05-0.52)] and greater hip circumference [OR 0.86 (0.81-
306 0.92)] are inversely associated with sarcopenia (Table 2).

307 Table 2: Multivariable analysis on variables associated with sarcopenia

Characteristic	Adjusted OR (95% CI)
Age, years	1.06 (1.01-1.12)
Sex	
Male	2.80 (1.12-7.02)*
Female	1
BMI, kg/m ²	
<18.5	2.34 (0.56-9.67)
18.5-22.9	1
23-27.4	0.53 (0.24-1.16)
27.5 and above	0.16 (0.05-0.52)***
HC, cm	0.86 (0.81-0.92)***
Physical Activity level	
Low	2.13 (1.17-3.89)*
Moderate to High	1

308 P values: * <0.05; ** <0.01; *** <0.001

309

310 *Factors associated with severe sarcopenia*

311 Among the variables investigated, severe sarcopenia in our setting is associated with

312 age [OR 1.10 (1.03-1.16)], males [OR 4.35 (1.5-12.64)], low physical activity [OR 2.78

313 (1.34-5.79)], and cognitive impairment with MMSE 23 or less [OR 2.26 (1.01-5.02)].

314 Higher BMI more than or equal to 27.5 [OR 0.20 (0.05-0.75)] and greater hip

315 circumference [OR 0.84 (0.78-0.91)] are inversely associated with sarcopenia (Table

316 3).

317 Table 3 Multinomial regression on association factors with sarcopenia and severe sarcopenia

Variables	Sarcopenia	
	Adjusted OR (95% C.I.)	p-value
Age	0.99 (0.93-1.06)	0.829
Sex		
Male	1.57 (0.45-5.43)	0.476
Female	Reference	
Race		
Chinese	-	
Malay	-	
Indian	Reference	
Others (2 Eurasians, 1 Sikh)	-	
Current Marital Status		
Single/Widowed/Divorced/Separated	1.46 (0.60-3.56)	0.405
Married	Reference	
Living Setup		
Alone	-	
With Tenant / Friend	Reference	
With Family / Caregiver	-	
Highest Educational Qualification*		
Below GCE "N" or "O" levels	1.81 (0.76-4.33)	0.182
GCE "N" or "O" level and above	Reference	
Smoking history		
Never smoker	Reference	
Ex or Current smoker	1.09 (0.38-3.12)	0.877
BMI		
Less than 18.5	2.37 (0.42-13.34)	0.329
18.5-22.9	Reference	
23-27.4	0.52 (0.20-1.41)	0.2
27.5 and above	0.08 (0.01-0.50)	0.007
Waist Circumference ^a , cm		

Males ≤90;	0.39 (0.11-1.37)	0.142
Females ≤80		
Males >90;	Reference	
Females >80		
Hip Circumference in cm	0.86 (0.78-0.94)	0.001
Waist-Hip Ratio (WHR) ^b		
Males 1.0 and below	1.69 (0.45-6.31)	0.432
Females 0.85 and below		
Males more than 1.0	Reference	
Females more than 0.85		
Physical Activity ^c		
Low	1.57 (0.71-3.48)	0.263
Moderate to high	Reference	
Sedentary Time in minutes/day	1.00 (1.00-1.00)	0.136
Malnutrition Risk		
No risk	Reference	
Moderate risk	1.05 (0.44-2.53)	0.91
Severe risk	0.75 (0.26-2.20)	0.603
MMSE		
Score 23 and less	1.28 (0.54-3.04)	0.579
Score 24 and more	Reference	
Charlson Comorbidity Index		
0	Reference	
1 and 2	0.81 (0.34-1.96)	0.642
3 and more	0.95 (0.30-3.00)	0.928
Ever infected by COVID-19 before recruitment into study		
No	Reference	
Yes	0.89 (0.41-1.94)	0.778
RDG group ^d		
Others (IV antibiotics, wound care, malignancy)	4.84 (1.07-22.03)	0.041
Stroke	4.39 (0.77-23.83)	0.095
Hip fracture	Reference	
Musculoskeletal conditions	2.57 (0.71-9.28)	0.149
Deconditioning	1.04 (0.20-5.42)	0.959
MBI score on admission		
MBI 0-60	1.47 (0.67-3.22)	0.342
MBI 61-100	Reference	

318

319

^acut-offs for waist circumference as per HPB Asia Pacific Consensus and International Diabetes Federation

320

^bcut-offs for WHC as per WHO classification of abdominal fatness

321 ^cas assessed using WHO GPAQ

322 ^dRehab Diagnostic Groups

323 *missing data n=2

324

325 Discussion

326 We found a high prevalence of sarcopenia in an inpatient post-acute rehabilitation
327 setting in Singapore. In addition, what is worrisome is that severe sarcopenia is highly
328 prevalent with 1 in 3 inpatients having severe sarcopenia. Our sarcopenia prevalence
329 is in keeping with worldwide literature where such post-acute units have the highest
330 prevalence of sarcopenia followed by nursing home residents, then hospitalized older
331 adults and lowest in community dwelling older adults.(48) This confirms the burden
332 of disease in units performing rehabilitation and suggests that patients should be
333 intervened earlier upstream even before they are being referred or admitted to such
334 settings. There is also a certain urgency to identify this group of patients for further
335 study and conduct interventions with the aim to reverse the sarcopenia.

336

337 Like many studies, we found that ageing is associated with sarcopenia.(21-23, 49) This
338 is in keeping with the observation where older adults lose muscle mass with increasing
339 age with intramuscular and intermuscular fat infiltration.(50-53) Many underlying
340 hypotheses for this had been proposed including role of chronic inflammation,
341 intracellular biochemical pathways, concurrent metabolic chronic diseases more
342 prevalent in older adults leading to the onset of sarcopenia.(54, 55) However,
343 interesting developments looking at birth weights and later onset sarcopenia seem to
344 hint at other factors that go beyond ageing as contributory factors for sarcopenia,
345 setting the stage for a comprehensive review at reversing sarcopenia at all levels.(56,
346 57)

347 Most global literature found a significant association between males and sarcopenia
348 like our study although there are some studies showed an association between
349 females and sarcopenia instead.(18, 19, 21, 22) Nonetheless, this highlights likely
350 unique gender differences in developments of sarcopenia.(21, 58) It has been
351 postulated that myostatin causing catabolism in males and reduced IGF-1 leading to
352 anabolic decline in females have a role in the sex differences in sarcopenia
353 development.(59, 60) Other clinical parameters such as men losing muscle strength
354 and testosterone faster than women also support the association of men being at
355 higher odds of sarcopenia than women.(61-65) Future trials are needed to formulate
356 sex specific interventions tailored to reverse sarcopenia so as to conclusively
357 determine the causal effects of these associations.

358

359 Consistent with literature, low physical activity has an inverse association with muscle
360 mass and higher odds of sarcopenia.(66-68) What remains debatable is designing an
361 evidence-based exercise regime to reverse sarcopenia. The differential role of aerobic,
362 resistance training and a combination of the types of physical activity may play
363 different roles in preventing or reversing sarcopenia.(69) Incorporating the right mix
364 for the best effect is currently a knowledge gap worth studying in the future.

365

366 Higher hip circumference being a surrogate measure of gluteal musculature is
367 understandably inversely associated with sarcopenia.(19, 70-72) In addition, our
368 study finds that a higher BMI is also protective of sarcopenia similar to other
369 studies.(18, 73-75)

370 There may be a few explanations for the above. Firstly, a higher BMI may translate to
371 increased load-bearing requirements during daily activities increasing muscle
372 mass.(76) Secondly, a higher BMI may be due to better nutritional intake with a study

373 showing associations between BMI and total protein intake.(77) Thirdly, BMI is likely
374 an inadequate surrogate measure of adiposity in older adults.(78, 79) In fact,
375 sarcopenic obesity (SO) prevalence defined with BMI underestimates those defined
376 by body fat percentages in the same cohort in a study.(74) Interestingly, a higher BMI
377 range, confers a paradoxical survival benefit in older adults.(80, 81) A study comparing
378 all-cause mortality within the same cohort between groups with BMI v.s. body fat
379 percentage measurements showed no increased mortality risk in apparently obese
380 category of BMI while those defined obese with body fat percentage measurements
381 did.(82)

382 Perhaps it is time to reconsider the utility of previously accepted BMI range pre-
383 defined in Asians older adults. Despite the limitations of BMI as a surrogate measure
384 of body fat composition, it is undeniably an easily obtainable measure in a busy setting
385 with limited resources. However, there is a research gap in defining what is a normal
386 BMI range correlating to sarcopenic outcomes in long term prospective prognosis
387 studies.

388

389 It may also be timely to standardise the definition of sarcopenic obesity using body
390 fat percentages norms in future Delphi consensus studies among content experts.

391 However more studies need to be done to correctly classify obesity using body fat
392 percentage adjusted for sex, age and race. Aligning sarcopenic obesity diagnostic

393 criteria will stimulate further research in this area and allow for confident synthesis of
394 data outcomes across different studies. This will pave the way for interventional trials.

395

396 In our study, cognitively impaired participants have a higher odd of severe sarcopenia
397 although not to sarcopenia while global literature found an association between

398 cognitive impairment and sarcopenia.(83) We believe the loss of association of
399 cognitive impairment with sarcopenia could be due to type 2 error.

400 Our study did not find an association between categories of nutritional risks and
401 sarcopenia on multivariate analysis although there was a statistically significant
402 association on univariate analysis. Again, this could be due to type 2 error. An
403 alternative explanation is because of the inherent differential property of a screening
404 tool and a full diagnostic assessment of nutritional state. For example, a study showed
405 GLIM assessment of nutrition predicted sarcopenia among malnourished participants
406 while a screening tool failed to do so.(84)

407

408 To our knowledge, this is the first inpatient study in Singapore to report sarcopenia
409 prevalence using AWGS diagnostic criteria. Our study affirms some of the common
410 associations associated with sarcopenia in line with global literature. This
411 foundational evidence will provide the possibility of developing technology or artificial
412 intelligence driven case finding for sarcopenia in an inpatient setting via a risk
413 calculator. This is especially important as clinicians face challenges with equipment
414 and manpower investiture with current diagnostic criteria of sarcopenia. Our study
415 will also provide the basis for future intervention targeted at risk factors in our
416 population to modify sarcopenic outcomes.

417 Some other strengths of our study include a reasonably large number of recruitments
418 with low dropouts and missing data, as well as the consecutive sampling methodology
419 for all patients admitted to OCH to achieve a more representative sample of the
420 population.

421

422 *Limitations*

423 This study has several limitations. Our single site study participants may not be
424 reflective of inpatients in other post-acute settings in other countries. Our findings
425 cannot be generalized to those with participants characteristics that were excluded
426 as per study protocol. Additionally, causal relationship of the associated factors
427 cannot be established as it is a cross-sectional study.

428 Our study estimated appendicular lean mass using the InBody S10 BIA which was not
429 validated locally. However, the use of a multifrequency BIA is an accepted method of
430 measurement by AWGS2019 with gender-specific cut-offs. The team utilised the
431 InBody S10 for its ability to perform measurements in a supine position, enabling
432 assessment among participants with functional limitations. Additionally, utilisation of
433 a BIA machine will allow for comparative data in future interventional studies
434 spanning across inpatient to the community, where access to DXA may be difficult.

435 The Jamar hydraulic hand dynamometer is the recommended brand for assessing
436 handgrip strength, however this study utilised the Baseline hydraulic hand
437 dynamometer instead for logistical reasons as multiple sets were readily available and
438 routinely used by the rehabilitation department therapists, who were the assessors
439 of handgrip for this study. The Baseline dynamometer has been validated against the
440 Jamar dynamometer to measure equivalently and hence can be used
441 interchangeably(85).

442

443 Conclusions

444 Our study found a high level of sarcopenia among inpatient older adults. We also
445 found that participants with increased age, male gender, and a lower physical activity
446 level were more likely to be sarcopenic, while those who had a higher hip
447 circumference and higher BMI of 27.5 and above were less likely to be sarcopenic. In

448 addition, cognitively impaired participants were more likely to be severely sarcopenic.
449 There is an urgent need to address the burgeoning burden with sarcopenia and
450 identify patients at higher risk of sarcopenia in post-acute settings in Singapore for
451 early intervention.

452

453 Acknowledgements: Nil

454 Conflict of interest: The authors declare no conflict of interest.

455

456 Author's contributions: Charmaine Tan was the study's principal investigator. J Aw
457 and Charmaine Tan were responsible for the conception of the study. J Aw, SSYS,
458 Doris L., Ganeshan K and LL Low were the co-investigators. J Aw and Charmaine Tan
459 were responsible for the study design. Charmaine Tan and SSYS were responsible
460 mainly in the coordination of the training of the interviewers. J Aw, Charmaine Tan,
461 XL Low, HY Quek and Andrea Ong took consent from the participants. XL Low, HY
462 Quek and Andrea Ong were responsible for double checking data collected. Doris L.,
463 SV Koh and Ganeshan K. were responsible for the measurement of participants for
464 sarcopenia. J Aw, Charmaine Tan, SSYS and Olivia Xia cleaned the data and double
465 checked the data output to ensure validity of the data. J Aw and Charmaine Tan
466 provided the initial draft of the manuscript. J Aw, Charmaine Tan, LL Low, SSYS and
467 Olivia Xia played a role in the interpretation of the data and revision of manuscript
468 critically for important intellectual content and agreed to the final submission.

469

470 Financial disclosure:

471 This study was funded by the 2021 SingHealth Regional Health System (RHS),
472 Population-based, Unified, Learning System for Enhanced and Sustainable Health
473 (PULSES) Grant ID: CGOCT21S06. Funds were used to recruit interns for coordinating
474 administrative duties of the study on a day to day basis with oversight from the P.I.
475 and Co-Is. Part of the fund was used to purchase the BIA InBody S10 and also a
476 laptop that is encrypted to perform data analysis together with acquisition of Stata
477 software licence.

478

479 **References**

- 480 1. Ageing and Health: World Health Organization; 2021 [14th Oct 2021].
481 Available from: [https://www.who.int/news-room/fact-sheets/detail/ageing-and-](https://www.who.int/news-room/fact-sheets/detail/ageing-and-health)
482 [health](https://www.who.int/news-room/fact-sheets/detail/ageing-and-health).
- 483 2. Elderly, Youth and Gender Profile: Department of Statistics, Singapore; 2021
484 [Available from: [https://www.singstat.gov.sg/find-data/search-by-](https://www.singstat.gov.sg/find-data/search-by-theme/population/elderly-youth-and-gender-profile/latest-data)
485 [theme/population/elderly-youth-and-gender-profile/latest-data](https://www.singstat.gov.sg/find-data/search-by-theme/population/elderly-youth-and-gender-profile/latest-data).
- 486 3. Cao X, Hou Y, Zhang X, Xu C, Jia P, Sun X, et al. A comparative, correlate
487 analysis and projection of global and regional life expectancy, healthy life
488 expectancy, and their GAP: 1995-2025. *J Glob Health*. 2020;10(2):020407.
- 489 4. Decade of Healthy Ageing: Plan of Action. World Health Organization; 2020.
490 p. 1-26.
- 491 5. Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A, et al.
492 Age-associated changes in skeletal muscles and their effect on mobility: an
493 operational diagnosis of sarcopenia. *J Appl Physiol* (1985). 2003;95(5):1851-60.
- 494 6. Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia,
495 dynapenia, and the impact of advancing age on human skeletal muscle size and
496 strength; a quantitative review. *Front Physiol*. 2012;3:260.
- 497 7. Buch A, Carmeli E, Boker LK, Marcus Y, Shefer G, Kis O, et al. Muscle function
498 and fat content in relation to sarcopenia, obesity and frailty of old age--An overview.
499 *Exp Gerontol*. 2016;76:25-32.
- 500 8. Aw J, Lee ES, Chiang G, Tan BY. A study on prevalence and associations of
501 non-robustness in older adults aged 65 years and above attending a general
502 practitioner clinic in Ang Mo Kio. *Singapore Med J*. 2021;62(6):311-4.
- 503 9. Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyère O. Health Outcomes
504 of Sarcopenia: A Systematic Review and Meta-Analysis. *PLoS One*.
505 2017;12(1):e0169548.
- 506 10. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al.
507 Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing*.
508 2019;48(1):16-31.
- 509 11. Xu J, Reijnierse EM, Pacifico J, Wan CS, Maier AB. Sarcopenia is associated
510 with 3-month and 1-year mortality in geriatric rehabilitation inpatients: RESORT. *Age*
511 *Ageing*. 2021;50(6):2147-56.

- 512 12. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of
513 sarcopenia in the United States. *J Am Geriatr Soc.* 2004;52(1):80-5.
- 514 13. Yoshimura Y, Wakabayashi H, Bise T, Nagano F, Shimazu S, Shiraishi A, et al.
515 Sarcopenia is associated with worse recovery of physical function and dysphagia and
516 a lower rate of home discharge in Japanese hospitalized adults undergoing
517 convalescent rehabilitation. *Nutrition.* 2019;61:111-8.
- 518 14. Pagotto V, Silveira EA. Methods, diagnostic criteria, cutoff points, and
519 prevalence of sarcopenia among older people. *ScientificWorldJournal.*
520 2014;2014:231312.
- 521 15. Yoshimura Y, Wakabayashi H, Bise T, Tanoue M. Prevalence of sarcopenia
522 and its association with activities of daily living and dysphagia in convalescent
523 rehabilitation ward inpatients. *Clin Nutr.* 2018;37(6 Pt A):2022-8.
- 524 16. Sánchez-Rodríguez D, Marco E, Miralles R, Guillén-Solà A, Vázquez-Ibar O,
525 Escalada F, et al. Does gait speed contribute to sarcopenia case-finding in a
526 postacute rehabilitation setting? *Arch Gerontol Geriatr.* 2015;61(2):176-81.
- 527 17. Sawaya Y, Ishizaka M, Kubo A, Shiba T, Hirose T, Onoda K, et al. The Asian
528 working group for sarcopenia's new criteria updated in 2019 causing a change in
529 sarcopenia prevalence in Japanese older adults requiring long-term care/support. *J*
530 *Phys Ther Sci.* 2020;32(11):742-7.
- 531 18. Chang CF, Yeh YL, Chang HY, Tsai SH, Wang JY. Prevalence and Risk Factors
532 of Sarcopenia among Older Adults Aged ≥ 65 Years Admitted to Daycare Centers of
533 Taiwan: Using AWGS 2019 Guidelines. *Int J Environ Res Public Health.* 2021;18(16).
- 534 19. Fung FY, Koh YLE, Malhotra R, Ostbye T, Lee PY, Shariff Ghazali S, et al.
535 Prevalence of and factors associated with sarcopenia among multi-ethnic
536 ambulatory older Asians with type 2 diabetes mellitus in a primary care setting. *BMC*
537 *Geriatr.* 2019;19(1):122.
- 538 20. Lu Y, Karagounis LG, Ng TP, Carre C, Narang V, Wong G, et al. Systemic and
539 Metabolic Signature of Sarcopenia in Community-Dwelling Older Adults. *J Gerontol A*
540 *Biol Sci Med Sci.* 2020;75(2):309-17.
- 541 21. Pang BWJ, Wee SL, Lau LK, Jabbar KA, Seah WT, Ng DHM, et al. Prevalence
542 and Associated Factors of Sarcopenia in Singaporean Adults-The Yishun Study. *J Am*
543 *Med Dir Assoc.* 2021;22(4):885.e1-.e10.
- 544 22. Chew STH, Tey SL, Yalawar M, Liu Z, Baggs G, How CH, et al. Prevalence and
545 associated factors of sarcopenia in community-dwelling older adults at risk of
546 malnutrition. *BMC Geriatr.* 2022;22(1):997.
- 547 23. Keng BMH, Gao F, Teo LLY, Lim WS, Tan RS, Ruan W, et al. Associations
548 between Skeletal Muscle and Myocardium in Aging: A Syndrome of "Cardio-
549 Sarcopenia"? *J Am Geriatr Soc.* 2019;67(12):2568-73.
- 550 24. Gao Q, Hu K, Yan C, Zhao B, Mei F, Chen F, et al. Associated Factors of
551 Sarcopenia in Community-Dwelling Older Adults: A Systematic Review and Meta-
552 Analysis. *Nutrients.* 2021;13(12).
- 553 25. Tan LF, Lim ZY, Choe R, Seetharaman S, Merchant R. Screening for Frailty
554 and Sarcopenia Among Older Persons in Medical Outpatient Clinics and its
555 Associations With Healthcare Burden. *J Am Med Dir Assoc.* 2017;18(7):583-7.
- 556 26. Ministry of Health S. Community Hospital Care - Handbook for Patients.
557 2017.
- 558 27. Bull FC, Maslin TS, Armstrong T. Global physical activity questionnaire
559 (GPAQ): nine country reliability and validity study. *J Phys Act Health.* 2009;6(6):790-
560 804.

- 561 28. Chu AH, Ng SH, Koh D, Müller-Riemenschneider F. Reliability and Validity of
562 the Self- and Interviewer-Administered Versions of the Global Physical Activity
563 Questionnaire (GPAQ). *PLoS One*. 2015;10(9):e0136944.
- 564 29. Win AM, Yen LW, Tan KH, Lim RB, Chia KS, Mueller-Riemenschneider F.
565 Patterns of physical activity and sedentary behavior in a representative sample of a
566 multi-ethnic South-East Asian population: a cross-sectional study. *BMC Public*
567 *Health*. 2015;15:318.
- 568 30. Chu AHY, Ng SHX, Koh D, Müller-Riemenschneider F. Domain-Specific Adult
569 Sedentary Behaviour Questionnaire (ASBQ) and the GPAQ Single-Item Question: A
570 Reliability and Validity Study in an Asian Population. *Int J Environ Res Public Health*.
571 2018;15(4).
- 572 31. National Health Survey 2010. Epidemiology & Disease Control Division
573 Ministry of Health, Singapore
- 574 32. National Population Health Survey 2019. Household Interview: Epidemiology
575 & Disease Control Division and Policy, Research & Surveillance Group
576 Ministry of Health and Health Promotion Board, Singapore.
- 577 33. Global Physical Activity Questionnaire (GPAQ) Analysis Guide. World Health
578 Organization.
- 579 34. Lim SL, Tong CY, Ang E, Lee EJ, Loke WC, Chen Y, et al. Development and
580 validation of 3-Minute Nutrition Screening (3-MinNS) tool for acute hospital patients
581 in Singapore. *Asia Pac J Clin Nutr*. 2009;18(3):395-403.
- 582 35. Lim SL, Ang E, Foo YL, Ng LY, Tong CY, Ferguson M, et al. Validity and
583 reliability of nutrition screening administered by nurses. *Nutr Clin Pract*.
584 2013;28(6):730-6.
- 585 36. Sahadevan S, Lim PP, Tan NJ, Chan SP. Diagnostic performance of two
586 mental status tests in the older chinese: influence of education and age on cut-off
587 values. *Int J Geriatr Psychiatry*. 2000;15(3):234-41.
- 588 37. Ng TP, Niti M, Chiam PC, Kua EH. Ethnic and educational differences in
589 cognitive test performance on mini-mental state examination in Asians. *Am J Geriatr*
590 *Psychiatry*. 2007;15(2):130-9.
- 591 38. Appropriate body-mass index for Asian populations and its implications for
592 policy and intervention strategies. *Lancet*. 2004;363(9403):157-63.
- 593 39. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide
594 definition. A Consensus Statement from the International Diabetes Federation.
595 *Diabet Med*. 2006;23(5):469-80.
- 596 40. Organization WH. Waist circumference and waist-hip ratio: report of a WHO
597 expert consultation. Geneva 8-11 December 2008.
- 598 41. World Health Organization, Regional Office for the Western Pacific. The
599 Asia-Pacific perspective : redefining obesity and its treatment. Sydney: Health
600 Communications Australia 2000.
- 601 42. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al.
602 Sarcopenia: European consensus on definition and diagnosis: Report of the
603 European Working Group on Sarcopenia in Older People. *Age Ageing*.
604 2010;39(4):412-23.
- 605 43. Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al.
606 Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. *J*
607 *Am Med Dir Assoc*. 2014;15(2):95-101.
- 608 44. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian
609 Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and
610 Treatment. *J Am Med Dir Assoc*. 2020;21(3):300-7.e2.

- 611 45. Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Manuel Gómez J,
612 et al. Bioelectrical impedance analysis-part II: utilization in clinical practice. *Clin Nutr.*
613 2004;23(6):1430-53.
- 614 46. Fess EE, Moran CA. American Society of Hand Therapists Clinical Assessment
615 Recommendations. United States of America August 1981. 17 p.
- 616 47. Prosthetists AAoOa. Five Time Sit to Stand Test (FTSST). 2017. p.
617 <https://www.youtube.com/watch?v=jPI-luRJ5A>.
- 618 48. Lardiés-Sánchez B, Sanz-Paris A, Boj-Carceller D, Cruz-Jentoft AJ. Systematic
619 review: Prevalence of sarcopenia in ageing people using bioelectrical impedance
620 analysis to assess muscle mass. *European Geriatric Medicine.* 2016;7(3):256-61.
- 621 49. Yuan S, Larsson SC. Epidemiology of sarcopenia: Prevalence, risk factors, and
622 consequences. *Metabolism.* 2023;144:155533.
- 623 50. Wilkinson DJ, Piasecki M, Atherton PJ. The age-related loss of skeletal
624 muscle mass and function: Measurement and physiology of muscle fibre atrophy
625 and muscle fibre loss in humans. *Ageing Res Rev.* 2018;47:123-32.
- 626 51. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. *Lancet.* 2019;393(10191):2636-46.
- 627 52. Marcus RL, Addison O, Kidde JP, Dibble LE, Lastayo PC. Skeletal muscle fat
628 infiltration: impact of age, inactivity, and exercise. *J Nutr Health Aging.*
629 2010;14(5):362-6.
- 630 53. Verdijk LB, Snijders T, Drost M, Delhaas T, Kadi F, van Loon LJ. Satellite cells
631 in human skeletal muscle; from birth to old age. *Age (Dordr).* 2014;36(2):545-7.
- 632 54. Dalle S, Rossmeislova L, Koppo K. The Role of Inflammation in Age-Related
633 Sarcopenia. *Front Physiol.* 2017;8:1045.
- 634 55. Biolo G, Cederholm T, Muscaritoli M. Muscle contractile and metabolic
635 dysfunction is a common feature of sarcopenia of aging and chronic diseases: From
636 sarcopenic obesity to cachexia. *Clinical Nutrition.* 2014;33(5):737-48.
- 637 56. Sayer AA, Syddall HE, Gilbody HJ, Dennison EM, Cooper C. Does sarcopenia
638 originate in early life? Findings from the Hertfordshire cohort study. *J Gerontol A*
639 *Biol Sci Med Sci.* 2004;59(9):M930-4.
- 640 57. Patel HP, Syddall HE, Martin HJ, Stewart CE, Cooper C, Sayer AA.
641 Hertfordshire sarcopenia study: design and methods. *BMC Geriatr.* 2010;10:43.
- 642 58. Ren X, Zhang X, He Q, Du L, Chen K, Chen S, et al. Prevalence of sarcopenia in
643 Chinese community-dwelling elderly: a systematic review. *BMC Public Health.*
644 2022;22(1):1702.
- 645 59. Tay L, Ding YY, Leung BP, Ismail NH, Yeo A, Yew S, et al. Sex-specific
646 differences in risk factors for sarcopenia amongst community-dwelling older adults.
647 *Age (Dordr).* 2015;37(6):121.
- 648 60. Sattler FR, Castaneda-Sceppa C, Binder EF, Schroeder ET, Wang Y, Bhasin S,
649 et al. Testosterone and growth hormone improve body composition and muscle
650 performance in older men. *J Clin Endocrinol Metab.* 2009;94(6):1991-2001.
- 651 61. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV,
652 et al. The Loss of Skeletal Muscle Strength, Mass, and Quality in Older Adults: The
653 Health, Aging and Body Composition Study. *The Journals of Gerontology: Series A.*
654 2006;61(10):1059-64.
- 655 62. Shimokata H, Ando F, Yuki A, Otsuka R. Age-related changes in skeletal
656 muscle mass among community-dwelling Japanese: a 12-year longitudinal study.
657 *Geriatr Gerontol Int.* 2014;14 Suppl 1:85-92.
- 658 63. Gallagher D, Visser M, De Meersman RE, Sepúlveda D, Baumgartner RN,
659 Pierson RN, et al. Appendicular skeletal muscle mass: effects of age, gender, and
660 ethnicity. *J Appl Physiol (1985).* 1997;83(1):229-39.

- 661 64. Mouser JG, Loprinzi PD, Loenneke JP. The association between physiologic
662 testosterone levels, lean mass, and fat mass in a nationally representative sample of
663 men in the United States. *Steroids*. 2016;115:62-6.
- 664 65. LeBlanc ES, Wang PY, Lee CG, Barrett-Connor E, Cauley JA, Hoffman AR, et
665 al. Higher Testosterone Levels Are Associated with Less Loss of Lean Body Mass in
666 Older Men. *The Journal of Clinical Endocrinology & Metabolism*. 2011;96(12):3855-
667 63.
- 668 66. Steffl M, Bohannon RW, Sontakova L, Tufano JJ, Shiells K, Holmerova I.
669 Relationship between sarcopenia and physical activity in older people: a systematic
670 review and meta-analysis. *Clin Interv Aging*. 2017;12:835-45.
- 671 67. Hughes VA, Roubenoff R, Wood M, Frontera WR, Evans WJ, Fiatarone Singh
672 MA. Anthropometric assessment of 10-y changes in body composition in the elderly.
673 *Am J Clin Nutr*. 2004;80(2):475-82.
- 674 68. Shephard RJ, Park H, Park S, Aoyagi Y. Objectively measured physical activity
675 and progressive loss of lean tissue in older Japanese adults: longitudinal data from
676 the Nakanojo study. *J Am Geriatr Soc*. 2013;61(11):1887-93.
- 677 69. Yoo SZ, No MH, Heo JW, Park DH, Kang JH, Kim SH, et al. Role of exercise in
678 age-related sarcopenia. *J Exerc Rehabil*. 2018;14(4):551-8.
- 679 70. Janghorbani M, Momeni F, Dehghani M. Hip circumference, height and risk
680 of type 2 diabetes: systematic review and meta-analysis. *Obes Rev*.
681 2012;13(12):1172-81.
- 682 71. Jayedi A, Soltani S, Zargar MS, Khan TA, Shab-Bidar S. Central fatness and
683 risk of all cause mortality: systematic review and dose-response meta-analysis of 72
684 prospective cohort studies. *Bmj*. 2020;370:m3324.
- 685 72. Snijder MB, Dekker JM, Visser M, Bouter LM, Stehouwer CD, Kostense PJ, et
686 al. Associations of hip and thigh circumferences independent of waist circumference
687 with the incidence of type 2 diabetes: the Hoorn Study. *Am J Clin Nutr*.
688 2003;77(5):1192-7.
- 689 73. Curtis M, Swan L, Fox R, Warters A, O'Sullivan M. Associations between Body
690 Mass Index and Probable Sarcopenia in Community-Dwelling Older Adults.
691 *Nutrients*. 2023;15(6).
- 692 74. Liu C, Cheng KY, Tong X, Cheung WH, Chow SK, Law SW, et al. The role of
693 obesity in sarcopenia and the optimal body composition to prevent against
694 sarcopenia and obesity. *Front Endocrinol (Lausanne)*. 2023;14:1077255.
- 695 75. Linge J, Heymsfield SB, Dahlqvist Leinhard O. On the Definition of Sarcopenia
696 in the Presence of Aging and Obesity-Initial Results from UK Biobank. *J Gerontol A*
697 *Biol Sci Med Sci*. 2020;75(7):1309-16.
- 698 76. Abramowitz MK, Hall CB, Amodu A, Sharma D, Androga L, Hawkins M.
699 Muscle mass, BMI, and mortality among adults in the United States: A population-
700 based cohort study. *PLoS One*. 2018;13(4):e0194697.
- 701 77. Moon K, Krems C, Heuer T, Hoffmann I. Association between body mass
702 index and macronutrients differs along the body mass index range of German adults:
703 results from the German National Nutrition Survey II. *J Nutr Sci*. 2021;10:e8.
- 704 78. Xu Z, Liu Y, Yan C, Yang R, Xu L, Guo Z, et al. Measurement of visceral fat and
705 abdominal obesity by single-frequency bioelectrical impedance and CT: a cross-
706 sectional study. *BMJ Open*. 2021;11(10):e048221.
- 707 79. Batsis JA, Mackenzie TA, Bartels SJ, Sahakyan KR, Somers VK, Lopez-Jimenez
708 F. Diagnostic accuracy of body mass index to identify obesity in older adults:
709 NHANES 1999-2004. *Int J Obes (Lond)*. 2016;40(5):761-7.
- 710 80. Winter JE, MacInnis RJ, Wattanapenpaiboon N, Nowson CA. BMI and all-
711 cause mortality in older adults: a meta-analysis. *Am J Clin Nutr*. 2014;99(4):875-90.

- 712 81. Donini LM, Pinto A, Giusti AM, Lenzi A, Poggiogalle E. Obesity or BMI
713 Paradox? Beneath the Tip of the Iceberg. *Front Nutr.* 2020;7:53.
- 714 82. Padwal R, Leslie WD, Lix LM, Majumdar SR. Relationship Among Body Fat
715 Percentage, Body Mass Index, and All-Cause Mortality: A Cohort Study. *Ann Intern*
716 *Med.* 2016;164(8):532-41.
- 717 83. Ohta T, Sasai H, Osuka Y, Kojima N, Abe T, Yamashita M, et al. Age- and sex-
718 specific associations between sarcopenia severity and poor cognitive function
719 among community-dwelling older adults in Japan: The IRIDE Cohort Study. *Frontiers*
720 *in Public Health.* 2023;11.
- 721 84. Lengelé L, Bruyère O, Beaudart C, Reginster J-Y, Locquet M. Malnutrition,
722 assessed by the Global Leadership Initiative on Malnutrition (GLIM) criteria but not
723 by the mini nutritional assessment (MNA), predicts the incidence of sarcopenia over
724 a 5-year period in the SarcoPhAge cohort. *Aging Clinical and Experimental Research.*
725 2021;33(6):1507-17.
- 726 85. Mathiowetz V, Vizenor L, Melander D. Comparison of Baseline Instruments
727 to the Jamar Dynamometer and the B&L Engineering Pinch Gauge. *The Occupational*
728 *Therapy Journal of Research.* 2000;20(3):147-62.
- 729




Figure 1: Process of identifying sarcopenia in our study population using Asian Working Group for Sarcopenia (AWGS) 2019 criteria (ASMI: appendicular skeletal muscle mass index; HGS: handgrip strength; PP: physical performance)